Kuznicki Law is investigating the proposed sale of CTI BioPharma Corp. (NasdaqCM: CTIC) to Swedish Orphan Biovitrum AB (“Sobi”). Under the terms of the proposed transaction, shareholders of CTI will receive only $9.10 in cash for each share of CTI that they own. Kuznicki Law is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
Please note that the merger is structured as a tender offer, such that time may be of the essence.